INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...

From June 1, the migraine prevention drug Emgality has been expanded on the Pharmaceutical Benefits Scheme, making it ...

INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently granted priority review to the supplemental Biologics License Application for Emgality ...

INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...

Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Emgality, a once-monthly, self-administered, subcutaneous injection, for the preventive ...

The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments "These ...

It happened! After yearning for the new “miracle” migraine drug, I was finally approved for monthly injections. So, that’s the good news. The bad news is that ...

Thousands of Australians living with frequent migraines will now be able to access a treatment many describe as life-changing ...

MINNEAPOLIS (CBSLocal) -- It is being called a breakthrough for migraine sufferers. A new FDA approved treatment called Emgality is the third in a class of new drugs that aim to stop the headaches ...